Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
about
Methotrexate and PralatrexateSystemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?T-cell lymphomas, a challenging disease: types, treatments, and future.Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.Novel therapeutic agents for cutaneous T-Cell lymphoma.Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphomaCutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.Doxycycline is an NF-κB inhibitor that induces apoptotic cell death in malignant T-cells.Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.Novel treatment avenues for peripheral T-cell lymphomas.Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.Novel therapies for cutaneous T-cell lymphoma: what does the future hold?Emerging drugs for T-cell lymphoma.The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.Targeted therapies for cutaneous T-cell lymphomas.Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides.Forodesine in the treatment of cutaneous T-cell lymphoma.Romidepsin for cutaneous T-cell lymphoma.Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.Periocular cutaneous anaplastic large cell lymphoma clearance with brentuximab vedotin.Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions.Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome.Monoclonal antibodies against cutaneous T-cell lymphomas.
P2860
Q28083080-ACD00480-9A40-4614-A259-15CEBDE290A5Q30239965-F08A803E-2179-49BD-A4BC-FBC831A63629Q30244553-ED5CCBBB-B040-4DA3-BB53-7A709FAE6B18Q33404897-7C6A21EB-0E49-4612-92E6-67F25091B15EQ33405882-7A589D4C-0FBE-4357-913B-B2004C0DD2D3Q33433565-3277EB2B-09CC-496F-9210-17B648091DB7Q33766600-561E899D-B588-4A06-BD1B-C903F327297FQ35222112-C4E3ACCB-B67D-4A9E-B269-9A0E01DAA5C8Q35859224-54C6E3B7-21CB-456C-9B4D-94732F3ED079Q36161365-7185D652-0F09-4E38-A72B-B05B2AA2ABA4Q36283958-B5D9E84F-8A0F-465E-BD13-FA66B8BF0CA1Q36470196-E7365EC7-D255-4905-876E-C37ED58FDF87Q37379370-951ED1BE-055A-4FA8-8B48-6B7043F73EC1Q37689051-E5201ADD-594A-4F2C-9B5E-BF72CDB948F8Q38042561-3F31F0F1-EBC2-493D-B35C-173F957A7FD2Q38045460-FC78C64F-DB2C-4878-BFE6-B2EB4E38F19CQ38100789-66996672-CD9A-4437-82BE-260B28271FD8Q38176398-657BA1CF-8270-4EB7-B515-68C35D1D0071Q38196943-F60DB30A-BB19-4408-97B3-B7C63A7FCC41Q38198754-CB72590D-D1D7-423E-B005-1DC0010903D0Q38212880-37B6723D-BD37-4E44-B8B6-B6798D1C3595Q38229634-738FA724-286A-4D4C-9A49-D3B31781D983Q38286313-578AD373-544F-4FF5-AAE7-4FEF4358C566Q38813983-FF543846-F9F5-4A83-9F20-C295AD0B4667Q39266443-9BD31C47-EE1E-439B-941B-D5FB045E1BFBQ39303355-43C6E522-3F14-4BD0-9D36-1892752E9B25Q39454734-63EB6239-E792-471E-815A-9D10940DE77EQ42158373-987A08EE-E82C-4CF9-BA22-D38D69D0A809Q46006814-F4723152-A772-416E-863E-BF496BB5DC6FQ47389863-273FA012-C397-4838-B622-6B265BDD44FAQ47902760-E2E30589-A753-4C7B-BF01-A4707FDF9E3EQ48254224-9EE0C772-0C8F-4A43-ABBF-DF5382DB7D39Q48296904-6E49C8E5-8F6A-4363-97CB-F410C4A27E9FQ51484852-FE9BA9ED-40D7-435F-8DF8-8A15BA7E6EB5Q51803389-467AEDAD-54E0-4C51-9820-735A727CA0B1
P2860
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Identification of an active, w ...... ory cutaneous T-cell lymphoma.
@ast
Identification of an active, w ...... ory cutaneous T-cell lymphoma.
@en
type
label
Identification of an active, w ...... ory cutaneous T-cell lymphoma.
@ast
Identification of an active, w ...... ory cutaneous T-cell lymphoma.
@en
prefLabel
Identification of an active, w ...... ory cutaneous T-cell lymphoma.
@ast
Identification of an active, w ...... ory cutaneous T-cell lymphoma.
@en
P2093
P1433
P1476
Identification of an active, w ...... ory cutaneous T-cell lymphoma.
@en
P2093
Andrei R Shustov
David C Fisher
Francine Foss
Jasmine M Zain
Madeleine Duvic
Maria L Delioukina
Mary Jo Lechowicz
Michael E Saunders
Nancy L Bartlett
Owen A O'Connor
P304
P356
10.1182/BLOOD-2011-11-390211
P407
P577
2012-03-06T00:00:00Z